News archive
Showing 777 results
October 2025
-
Media Release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo… -
Story Education and Awareness
Five Questions with Katie Mazuk, Novartis US Chief Patient Experience Officer
In this interview, Katie shares the experiences that have shaped her leadership philosophy, her vision for pioneering new approaches in patient support, and why she believes the future of healthcare lies in combining technological innovation with genuine connection.
-
Media Release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-… -
Media Release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor… -
Media Release
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1… -
Story Education and Awareness
High Lipoprotein(a) Explained: What You Need to Know about This Hidden, Emerging Indicator for Heart Disease
High Lp(a) is an inherited condition that can independently increase the risk of heart disease1,2,3. Read on.
-
Story Education and Awareness
5 Key Insights Into How Women Really Feel About Their Breasts
How do women’s feelings about their breasts impact breast health? We asked 3000 women in the first ever Novartis Breast Health & Experience Index.
September 2025
-
Media Release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-controlled disease observed as fast as two… -
Media Release
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products;… -
Statement
Bringing breakthroughs to more patients
-
Media Release
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after… -
Story Education and Awareness
How Social Workers Can Make a Difference for Advanced Prostate Cancer Patients
In the complex journey of advanced prostate cancer, care doesn’t just happen in the clinic. It includes everyday emotional and practical challenges patients and families face. Social workers help bridge these gaps.